How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


New bifunctional Prodrugs with cleavable linker for targeted tumor therapy (ADC)

Organization name

MBM ScienceBridge GmbH


Antibody tumor therapies have provided therapeutic benefit to patients with cancer, autoimmune diseases and other serious medical conditions. However, many antibodies lack sufficient intrinsic anti-tumor activity to be used as first-line therapeutics. Scientists at the University of Göttingen developed new and highly potent drugs with cleavable chemical linkers to develop tumor specific antibodies for selective and highly effective tumor therapy (ADC).


Selective tumor therapy combines the benefits from classical chemotherapy and antibody tumor therapy by providing antibody-drug-conjugates (ADC). These conjugates must provide safe medical application (prodrugs) and extremely high toxicity within the targeted tumor cell (activated drug). Thus, there is a high medical unmet need to provide ADCs with stable but cleavable chemical linker to safely and effectively release highly toxic payloads.

Our Solution

Scientists at the University of Göttingen developed new and highly potent prodrugs/drugs with cleavable chemical linkers for ADCs. The soluble prodrugs are activated into highly cytotoxic drugs (IC50 in the pico-molar range) only in targeted tumor cells.


  • New chemical linker design based on our 2nd generation bifuncional prodrugs/drugs (Duocarmycin origin).
  • Prodrug has low cytotoxicity, whereas drug is highly totoxic in low pico-molar range.
  • Chemical linker with cleavable group for release and activation of prodrug into drug inside targeted tumor cell.
  • Expected improvement in safety through bigger therapeutic window (QIC50 Prodrug/Drug = 1.000.000).
  • Specific and effective chemical coupling to antibodies.
  • Payload with new MoA: highly toxic non-DNA binding alkylating agent.


ADC Tumor Therapy.

Developmental Status

In vitro tested prodrugs/drugs having cleavable linker for direct antibody coupling.

Patent Status

A German priority patent application has been filed (Applicant: Georg-August-University of Göttingen public law foundation).


  • Tietze et al. Angew. Chem. Int. Ed. 2010, 49(40), 7336-9.
  • Wirth et al. Angew. Chem. Int. Ed. 2012, 51(12), 2874-7.
  • Wirth et al. Angew. Chem. Int. Ed. 2013, 125(27), 7059-63.
  • Chen et al. Mol Pharm. 2013 May 6;10(5):1773-82.
  • Koch et al. Angew. Chem. Int. Ed. 2015, 54(46), 13550-4.
  • WO2007089149
  • WO2011054837

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries